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In utero hematopoietic cell transplantation (IUHCTx) is a promising strategy to circumvent
the challenges of postnatal hematopoietic stem cell (HSC) transplantation. The goal of
IUHCTx is to introduce donor cells into a naïve host prior to immune maturation, thereby
inducing donor–specific tolerance. Thus, this technique has the potential of avoiding host
myeloablative conditioning with cytotoxic agents. Over the past two decades, several
attempts at IUHCTx have been made to cure numerous underlying congenital anomalies
with limited success. In this review, we will briefly review the history of IUHCTx and give
a perspective on alpha thalassemia major, one target disease for its clinical application.
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HISTORY OF IUHCTx
In utero hematopoietic cell transplantation offers the benefit
of treating congenital stem cell disorders prior to birth while
avoiding host myeloablative conditioning with cytotoxic agents
(Golombeck et al., 2006; Vrecenak et al., 2014). The idea that
exposure to foreign antigens can lead to tolerance was first rec-
ognized by Owen (1945), with the discovery that monochorionic
dizygotic cattle were tolerant of long-lived chimeric cells from
their siblings. Since then, natural chimerism has been described
in both human and non-human primates (Picus et al., 1985; van
Dijk et al., 1996), although it was not until the late 1970s that
Fleischman and Mintz reported the first successful chimerism
resulting from IUHCTx. Using a c-Kit deficient mouse which
resulted in genetic anemia, they were able to reverse the ane-
mia by transplanting adult allogeneic bone marrow stem cells
into the placenta (Fleischman and Mintz, 1979). Since then,
IUHCTx has proven to be successful in many animal models
including mice (Carrier et al., 1995), goats (Pearce et al., 1989),
dogs (Blakemore et al., 2004; Peranteau et al., 2009; Vrecenak
et al., 2014), sheep (Flake et al., 1986), and non-human pri-
mates (Harrison et al., 1989; Tarantal et al., 2000). Mouse models
have been used to manipulate various aspects of the maternal
(Merianos et al., 2009; Nijagal et al., 2011) and fetal (Misra et al.,
2009; Nijagal et al., 2013) immune systems to understand the
mechanism of tolerance induction. In the large animal models,
which are a necessary step to understanding the effects of immune
ontogeny of human fetuses, high dose transplantation has enabled
achieving clinically relevant levels of chimerism (Vrecenak et al.,
2014).
In humans, the first successful IUHCTxwas performed for bare
lymphocyte syndrome (Touraine et al., 1989). Successful trans-
plantation of fetuses with severe combined immunodeficiency
(SCID) was also achieved by several groups (Flake et al., 1996;
Wengler et al., 1996). However, subsequent attempts into fetuses
with various disease processes including hemoglobinopathies,
chronic granulomatous disease, Chediak–Higashi syndrome and
inborn errors of metabolism were met with limited success
(reviewed in Vrecenak and Flake, 2013). These limitation have led
several groups to explore barriers to engraftment which include
the fetal and maternal immune systems, the competitive disad-
vantage of donor cells when transplanted into an intact fetal host,
and a lack of space within hematopoietic niches (reviewed in
Nijagal et al., 2012). Since it has been shown that the maternal
immune system (both T cells and B cells) is a critical barrier to
engraftment (Merianos et al., 2009; Nijagal et al., 2011), clinical
efforts should focus on transplantation of maternal (or mater-
nally matched) hematopoietic cells. The levels of engraftment
can also be increased by transplanting a high number of CD34
enriched, CD3 depleted bone marrow cells using an intravas-
cular (as opposed to intraperitoneal) approach (Vrecenak et al.,
2014). Further efforts to improve the competitive advantage of
the transplanted cells and to create space for their engraftment
in the hematopoietic niche will likely be necessary. For example,
we have recently demonstrated that selective in utero depletion of
host HSCs using an antibody against the c-Kit receptor (ACK2)
results in therapeutic levels of engraftment after neonatal trans-
plantation (Derderian et al., 2014), providing a proof of concept
for such a conditioning approach in the fetal environment. This
approach may also avoid the need for conventional myeloablative
drugs such as busulfan that could cause tissue cytotoxicity in utero.
Finally, transplantation prior to the development of circulating T
cells is likely critical and further measures to promote fetal toler-
ance induction for example, by co-transplantation of regulatory T
cells, should be explored.
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THERAPEUTIC POTENTIAL OF IUHCTx FOR
ALPHA-THALASSEMIA
In utero hematopoietic cell transplantation has excellent potential
to treat common hemoglobinopathies such as sickle cell disease
and thalassemias. In particular, alpha thalassemia major can be
diagnosed early in gestation and poses risks to the developing fetus
including hydrops fetalis, which may provide further justification
for an in utero intervention.
Alpha-thalassemia is one of the most common single-gene dis-
orders, affecting approximately 5%of peopleworldwide (Lau et al.,
1997; Chui and Waye, 1998; Leung et al., 2008). It is an auto-
somal recessive disease, resulting from DNA sequence deletions
on chromosome 16. At least 40 deletions are known (reviewed
in Vichinsky, 2009), the most common of which is the South-
east Asian deletion (−SEA; Chui and Waye, 1998; Hoppe, 2009).
Since there are 4 alleles coding for the alpha-globin protein,
the disease can present as a spectrum. The homozygous form
(−/−), often referred to as Hb Bart’s, results in the absence of
all alpha-globin production. Unaffected chains accumulate and
form tetramers unable to transport oxygen, ultimately leading to
hypoxia, non-immune fetal hydrops, and in utero demise (Leung
et al., 2008).
EARLY DIAGNOSIS IN UTERO
Advancements in prenatal diagnostic tools have provided means
for early diagnosis of many congenital anomalies, including alpha-
thalassemia. Anemia caused by alpha-thalassemia can be detected
on ultrasound by an increase in the cardiothoracic ratio, an
increase in middle cerebral artery peak systolic velocities, and
the presence of non-immune hydrops. These changes have been
detected as early as 12 weeks’ gestation (Lam et al., 1999; Li et al.,
2007), which is well within the window of optimal timing for
IUHCTx. Once anemia is suggested on ultrasound, the diagnosis
of alpha-thalassemia requires fetal DNA for genetic sequencing.
Currently, the most common modalities to obtain fetal DNA for
analysis are amniocentesis, which can be performed as early as
16 weeks’ gestation with only a 0.5% risk of fetal demise (No
authors, 1976), or chorionic villus sampling, which is performed
as early as 10 weeks’ gestation (Nicolaides et al., 1994; Sundberg
et al., 1997). More recently, genetic disorders have been diag-
nosed using cell-free fetal DNA, which is detectable in maternal
serum as early as 7 weeks’ gestation (Lo et al., 1998). Advances
in laboratory technology have increased the likelihood that we
will soon be able to reliably diagnose alpha thalassemia major
prenatally with maternal plasma (Sirichotiyakul et al., 2012; Ge
et al., 2013). Although this strategy has great potential, detecting
complex mutations of alpha-thalassemia major remains a chal-
lenge. It appears likely soon women at risk for carrying a fetus
with Hb Bart’s will have the opportunity to undergo cell-free fetal
DNA testing not only before the onset of fetal hydrops but at a
time when the fetus is still in an immune tolerant state (Ge et al.,
2013).
IN UTERO MANIFESTATION
Fetuses with Hb Bart’s produce aberrant alpha-globin, which
results in accumulation of dysfunctional hemoglobin tetramers,
and impaired oxygen transportation. Definitive erythro-
cytes, composed predominantly of fetal hemoglobin (α2γ2),
begin circulating at 10 weeks’ gestation (Migliaccio and
Papayannopoulou, 2001). In utero, Hb Bart’s leads to anemia,
heart failure, fetal growth restriction, oligohydramnios, and non-
immune hydrops (Fucharoen et al., 1991), which historically was
considered to be a harbinger of fetal demise (Laros, 1994). More
recently, in utero exchange transfusion, which removes the dys-
functional hemoglobin, has been shown to reverse anemia, fetal
growth restriction, and oligohydramnios (Dwinnell et al., 2011).
However, this temporizing therapy is directed toward symptom
relief and not curing the underlying disorder. An alternative strat-
egy would be to offer IUHCTx to cure the genetic anemia even
before the onset of any symptoms.
Table 1 | In utero transplantation for alpha-thalassemia.
Case GA at diagnosis
(weeks)
GA at transplant
(weeks)
Cell source Cell number Route Engraftment Reference
1 10 13, 19, and 24 Paternal CD34+ BM
cells
3 × 106/kg i.p., i.v., i.v. CB at Birth and BM at
3 months – detectable alpha
globin but no donor cell
engraftment detected
Hayward et al.
(1998)
2 N/A 18 MaternalT -cell
depleted BM
6.3 × 108 i.p. CB at 20, 22, and 24
weeks – no engraftment
Extramedullary engraftment
on autopsy
Cowan and
Golbus (1994)
3 13 15, 31 Cryopreserved FL
from abortions
between 5 and
10 weeks’ gestation
2.2 × 1010,
2.7 × 1010
i.p., i.v. CB at 29 weeks GA – no
donor DNA or alpha globin
No postnatal donor cell
engraftment detected
Westgren
et al. (1996)
GA, gestational age; BM, bone marrow; kg, kilogram; i.p., intraperitoneal; i.v., intravenous; CB, cord blood; FL, fetal liver. N/A, not available.
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CURRENT IN UTERO THERAPY
Nearly 20 documented cases of Hb Bart’s have been treated with
in utero transfusion and outcomes have been generally favorable
(Carr et al., 1995; Singer et al., 2000; Zhou et al., 2001; Lucke et al.,
2005;Weisz et al., 2009; Yi et al., 2009; Dwinnell et al., 2011). How-
ever, these children are transfusion dependent and require iron
chelators to prevent complications resulting from iron overload
such as cirrhosis and insulin dependent diabetes. Neonatal com-
plications include cognitive and limb reduction defects (Dwinnell
et al., 2011). Among fetuses who do not undergo blood transfu-
sions and survive to birth, 25–50% are affected by neurological or
developmental shortcomings (Lucke et al., 2005; Lee et al., 2007),
presumably from prolonged in utero hypoxemia. However, fetuses
transfused early in gestation have a much lower incidence of cog-
nitive and limb reduction defects. Despite our awareness that
this process begins in utero, the only prenatal therapy available
is in utero transfusions, which is merely directed at symptom
relief.
CLINICAL EXPERIENCE WITH IUHCTx FOR
ALPHA-THALASSEMIA
There have been three attempts to treat alpha-thalassemia with
IUHCTx (Table 1) and only one has demonstrated donor cell
chimerism on autopsy. Each case used various strategies, mak-
ing them difficult to compare. The timing of in utero trans-
plantation differed, with cases #1 and #3 performed earlier in
gestation (13 and 15 weeks, respectively) while case #2 was per-
formed later (18 weeks). The source of donor cells differed
as well. Case #2 used maternally derived bone marrow HSCs
and was the only one with evidence of microchimerism on
autopsy (termination was pursued at 24 weeks’ gestation after no
evidence of engraftment was demonstrated by cord blood sam-
pling). This observation is supported by experiments in mice
demonstrating that maternally derived HSCs engraft better than
paternally derived HSCs (Merianos et al., 2009; Nijagal et al.,
2011).
While we cannot draw any definitive conclusions from these
attempts, strategies to improve engraftment are necessary. In each
case, the first series of transplanted cells were injected into the
peritoneal cavity, whereas evidence in animal models now sup-
ports that intravascular infusion is more likely to establish stable
donor engraftment. Since fetuseswithHbBart’swill be transfusion
dependent, transplantation may be performed at the same time as
an intrauterine transfusion. Based on animal models, transplan-
tation of T-cell depleted, CD34 enriched maternal-derived HSCs
should avoid a maternal immune response against the graft as
well as taking advantage of pre-existing fetal tolerance to mater-
nal cells. Additional areas to explore to improve engraftment are
ex vivo manipulation to increase HSCs proliferative ability and
homing potential [reviewed in Peranteau et al. (2009) in this issue]
as well as fetal conditioning with non-myeloablative agents such
as antibodies against the c-Kit receptor.
In summary, IUHCTx has only been successful in fetuses with
SCID and the subsequent lack of success in other diseases has left
the field undervalued. With advancements in technical strategies
and a new repertoire of therapies, it is time to revisit the idea
of IUHCTx for hemoglobinopathies. As with all fetal treatment
endeavors, careful patient selection, meticulous attention to tech-
nical details, and accurate reporting of results will be critical to the
success of future clinical trials.
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